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Collaborative activities and treatment outcomes in patients 
with HIV-associated tuberculosis in Viet Nam
T. T. T. Huyen,1 N. V. Nhung,1 H. D. Shewade,2 N. B. Hoa,1,3 A. D. Harries3,4
One of the most important threats to the success-ful global control of tuberculosis (TB) is human 
immunodeficiency virus (HIV) associated TB (TB-HIV). 
In 2014, there were an estimated 9.6 million patients 
with active TB, of whom 1.2 million (12%) were co-in-
fected with HIV.1 Of these co-infected patients, 390 000 
(33%) died because of TB,1 an unacceptable mortality 
rate given that TB can be successfully cured with stan-
dard anti-tuberculosis treatment regimens and HIV can 
be treated with antiretroviral therapy (ART).
In March 2012, the World Health Organization 
(WHO) released an updated policy document on col-
laborative TB-HIV activities to reduce the burden of 
dual disease, focusing on 1) mechanisms for delivering 
integrated TB and HIV services; 2) reducing the bur-
den of TB in people living with HIV by early ART and 
the ‘Three Is’, i.e., Intensified TB case finding, Isonia-
zid preventive therapy and Infection control at all 
clinical encounters; and 3) reducing the burden of 
HIV in patients with presumptive or diagnosed TB 
through a strategy of HIV testing and cotrimoxazole 
preventive therapy (CPT) and ART for those found to 
be HIV-infected.2
Viet Nam is one of the 22 high-burden TB coun-
tries, with TB prevalence estimated in 2014 at 198 per 
100 000 population and incidence at 140/100 000.1 
There is also a high burden of HIV: in 2014 there were 
an estimated 250 000 people living with HIV (PLHIV), 
constituting 0.5% of the adult population aged 15–49 
years.3 As a result, there is a sizeable burden of TB-HIV. 
Rates of HIV testing and collaborative TB-HIV activities 
have been gradually improving in Viet Nam over the 
last few years, but despite this, treatment outcomes in 
HIV-infected TB patients are poor, with less than 75% 
successfully completing treatment compared with 
overall treatment success rates of nearly 90% for all 
new and relapse TB cases registered nationally.1
Ho Chi Minh City (HCMC) is the main problem 
area. In 2013, 16% of all notified TB cases and about 
one third of all TB-HIV patients in Viet Nam were 
from HCMC, and these TB-HIV patients had a low 
treatment success rate of about 65% (source: National 
Tuberculosis Control Programme [NTP], based on 
1553 TB-HIV patients reported in the aggregate data-
base for HCMC in 2013). A major contributor to poor 
treatment outcomes is high case fatality, but this ad-
verse outcome and its associated factors have not 
been formally studied. A survey in HCMC in 1998–
2000 found a case fatality rate of 30% in TB-HIV pa-
tients.4 Case fatality and other adverse treatment out-
comes may be higher in patients with smear-negative 
TB and recurrent TB,5 and this again has not been 
formally studied. The NTP needs to better understand 
how TB-HIV collaborative activities are implemented 
in the whole country and its different regions, in-
cluding HCMC, and, in individual co-infected pa-
tients, how these might relate to TB treatment 
outcomes.
This study was planned with two specific objec-
tives: 1) to describe the relationship between HIV test-
ing among TB patients, and CPT and ART uptake and 
TB treatment outcomes among TB-HIV patients at na-
tional level in Viet Nam between 2011 and 2013; and 
2) to determine the association between demographic 
and clinical features in patients with TB-HIV and ad-
verse TB treatment outcomes in HCMC in 2013.
METHODS
Study design
The study assessed TB-HIV collaborative activities and 
treatment outcomes through 1) a review of aggregate 
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Setting: The National Tuberculosis (TB) Programme in 
Viet Nam and Ho Chi Minh City (HCMC).
Objectives: To determine 1) at national level between 
2011 and 2013, the relationship between human immu-
nodeficiency virus (HIV) testing, uptake of TB-HIV inter-
ventions and adverse treatment outcomes among TB-HIV 
patients; and 2) in HCMC in 2013, patient characteristics 
associated with adverse outcomes.
Design: An ecological study reviewing aggregate nation-
wide data and a retrospective cohort review in HCMC.
Results: Nationwide, from 2011 to 2013, HIV testing in-
creased in TB patients from 58% to 68% and antiretrovi-
ral therapy (ART) increased in TB-HIV patients from 54% 
to 63%. Adverse treatment outcomes in TB-HIV patients 
increased from 24% to 27%, largely due to transfer out 
(5–9% increase) and death. The Northern and Highland 
regions showed poor uptake of TB-HIV interventions. In 
HCMC, 303 (27%) of 1110 TB-HIV patients had adverse 
outcomes, with higher risks observed in those with previ-
ously treated TB, those diagnosed as HIV-positive before 
TB onset and those never placed on cotrimoxazole or 
ART.
Conclusion: Despite improving HIV testing rates and TB-
HIV interventions, adverse outcomes in TB-HIV patients 
remain at about 26%. Characteristics predicting higher 
risk of adverse outcomes must be addressed if Viet Nam 
wishes to end the TB epidemic by 2030.
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nationwide data (ecological design), and 2) a retrospec-
tive record review of individual patients registered in 
HCMC (cohort design).
Setting
General setting
Viet Nam is an Asian country of wide topographical di-
versity, with mountainous, mid-land and lowland ar-
eas and a coastal strip. The total population is 91 mil-
lion, with 28% living in urban areas. Administratively, 
Viet Nam has eight regions, 63 provinces, 687 cities 
and districts and 11 035 communes (Figure 1). HCMC, 
a city in the South-East region of Viet Nam, has a pop-
ulation of 8 million, making it the most populous met-
ropolitan area in the country.
Study setting
TB-HIV collaborative activities started under the NTP 
in 2007 in 10 provinces, including HCMC. By Febru-
ary 2014, 53 provinces were reporting on the imple-
mentation of TB-HIV collaborative activities. The roles 
of the TB and HIV programmes in service delivery for 
co-infected patients are clearly described in the na-
tional guidelines.6–8 In brief, PLHIV diagnosed during 
the study period were eligible for ART based on the 
WHO 2010 guidelines of a CD4 cell count 350 cells/
µl or being at WHO clinical stage 3 or 4.9 All PLHIV are 
screened for TB at each clinic visit, and if TB is sus-
pected they are referred for TB investigations in line 
with NTP guidelines. For all TB patients registered in 
NTP clinics, an enquiry is made about HIV status, and 
if the status is unknown or previously negative, pro-
vider-initiated HIV testing and counselling is under-
taken. According to national guidelines all TB-HIV pa-
tients are eligible for CPT and ART simultaneously 
with anti-tuberculosis treatment.
All patients are monitored during treatment using 
standard outcome definitions in line with WHO rec-
ommendations.10 The main monitoring tools are pa-
per-based treatment cards and registers, with the data 
then single-entered into an electronic web-based sys-
tem (the Viet Nam Information Management Elec-
tronic System [VITIMES]).
Study population
For the review of aggregate nationwide data, the study 
population included all TB patients registered in Viet 
Nam between 2011 and 2013. For the record review of 
individual-level data, the study population included 
all TB-HIV patients registered in HCMC in 2013.
Data variables, sources of data and data collection
For the nationwide aggregate data, variables included 
year, region, TB patients stratified by all TB types and 
new smear-positive pulmonary tuberculosis (PTB), HIV 
testing among TB patients, HIV-positive status, and 
CPT uptake, ART uptake and anti-tuberculosis treat-
ment outcomes in those with TB-HIV. For the record 
review of individual-level data, variables included age, 
sex, TB type and category, HIV testing, CPT initiation, 
ART initiation and TB treatment outcomes. Adverse 
treatment outcomes were defined as death, failure, loss 
to follow-up and transfer out combined. The data 
source was VITIMES. Data were collected between 
March and November 2015.
Analysis and statistics
The data were extracted into a Microsoft Office Excel 
spreadsheet (Microsoft Corp, Redmond, WA, USA) and 
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FIGURE 1 Map of Viet Nam showing the eight regions and TB case notification rates in 2013. 
TB = tuberculosis.
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imported and analysed in EpiData analysis software (version 
2.2.2.183, EpiData Association, Odense, Denmark). For aggregate 
data, frequencies and proportions were analysed for HIV testing, 
HIV-positive status and CPT and ART uptake. For individual pa-
tient data, the association between demographic and clinical fac-
tors and adverse treatment outcomes was summarised using rela-
tive risk (RR) and 95% confidence interval (CI).
Ethics approval
Permission to carry out the study was obtained from the NTP, Viet 
Nam. Ethics approval was obtained from the Ethics Advisory 
Group (EAG) of the International Union against Tuberculosis and 
Lung Disease (The Union), Paris, France. As the study was based 
on already collected routine data, the EAG waived the need for 
informed patient consent.
RESULTS
The annual results of HIV testing, HIV-positive status and CPT 
and ART uptake in TB patients found to be HIV-positive are 
shown in Table 1. Results were fairly similar for patients with all 
types of TB and those with new smear-positive PTB. Over the 3 
years, the annual number of notified TB cases remained stable, 
the proportion tested for HIV gradually increased while the pro-
portion found to be HIV-positive gradually decreased. For those 
found to be HIV-positive, there was a small gradual decrease in 
CPT uptake and an increase in ART uptake, resulting in about 
65% of patients receiving both types of medication in 2013.
The results of HIV testing, HIV-positive status and CPT and ART 
uptake for the 3 years combined for patients with all types of TB in 
each region are shown in Table 2. There were variations between 
regions. In the South-East region, where the number of cases of all 
types of TB was the highest, the highest rates of HIV testing and 
uptake of CPT and ART were observed among the 10% of patients 
found to be HIV-positive. In contrast, the Highland region had the 
lowest HIV testing rate, with poor uptake of CPT and ART. Similar 
poor rates of testing and HIV interventions were found in the 
three Northern regions. These results were replicated for patients 
with new smear-positive PTB (data not shown).
Treatment outcomes for patients registered annually in Viet 
Nam with TB-HIV are shown in Table 3. For patients with all 
types of TB and new smear-positive PTB, treatment success varied 
between 69% and 76%, with a small decrease occurring annually 
during the 3 years. The main adverse outcomes were death and 
transfer out, with a slight decrease in deaths and an increase in 
transfers out during the 3 years.
Figure 2 shows CPT and ART uptake and adverse treatment 
outcomes in TB-HIV patients in each region. The Highland region 
had poor uptake of HIV interventions and high rates of adverse 
outcomes (27%), which over the 3 years comprised death at 18% 
and transfer out at 7%, with annual rates being fairly similar. The 
South-East region had a generally good uptake of CPT and ART. 
However, this region had the highest rate of adverse outcomes 
(31%), which over the 3 years comprised death at 13% and trans-
fer out at 11%, with annual deaths decreasing from 15% to 13% 
and annual transfers out increasing from 6% to 13%.
TABLE 1 HIV testing, HIV positivity, CPT and ART status in patients registered for TB each year, Viet Nam, 2011–2013
Year
All patients
n
HIV test performed
n (%)
HIV-positive
n (%)*
CPT
n (%)†
ART
n (%)†
For patients with all types of TB
 2011 100 518 58 506 (58) 4692 (8) 3412 (73) 2509 (54)
 2012 103 906 64 546 (62) 4695 (7) 3205 (68) 2849 (61)
 2013 100 721 68 220 (68) 4407 (6) 2936 (67) 2856 (65)
For patients with new smear-positive pulmonary TB
 2011 50 751 29 245 (58) 1934 (7) 1296 (67) 939 (49)
 2012 51 033 32 057 (63) 1909 (6) 1257 (66) 1043 (55)
 2013 50 031 34 673 (69) 1780 (5) 1094 (62) 1028 (58)
* Proportion of patients tested for HIV.
† Proportion of patients testing HIV positive.
HIV = human immunodeficiency virus; CPT = cotrimoxazole preventive therapy; ART = antiretroviral therapy; TB = tuberculosis.
TABLE 2 HIV testing, HIV positivity, CPT and ART status in patients registered for all types of TB in each region, Viet Nam, 2011–2013
Region
All TB
n
HIV testing performed
n (%)
HIV-positive
n (%)*
CPT
n (%)†
ART
n (%)†
All regions 305 145 191 272 (63) 13 794 (7) 9553 (69) 8214 (60)
 Red River Delta 56 297 36 935 (66) 2198 (6) 1563 (71) 1151 (52)
 North East 24 145 12 038 (50) 1246 (10) 441 (35) 504 (40)
 North West 3511 1814 (52) 259 (14) 35 (14) 90 (35)
 North Central Coast 30 011 11 812 (39) 618 (5) 175 (28) 190 (31)
 South Central Coast 25 826 10 317 (40) 186 (2) 126 (68) 120 (65)
 Highland 8054 2853 (35) 71 (3) 24 (34) 26 (37)
 South East 82 084 68 475 (83) 6734 (10) 5452 (81) 4633 (69)
 Mekong River Delta 75 217 47 028 (63) 2482 (5) 1737 (70) 1500 (60)
* Proportion of patients tested for HIV.
† Proportion of patients testing HIV-positive.
HIV = human immunodeficiency virus; CPT = cotrimoxazole preventive therapy; ART = antiretroviral therapy; TB = tuberculosis.
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In 2013, there were 1553 TB-HIV patients registered in the aggre-
gate database in HCMC, of whom 1273 (82%) were documented in 
the VITIMES individual case base data file. Of these, no treatment 
outcomes were recorded for 163 (12.8%). Treatment outcomes (in-
cluding loss to follow-up) were therefore reported in 1110 individual 
patients. Adverse treatment outcomes amongst these 1110 TB-HIV 
patients in relation to patient characteristics are shown in Table 4. 
Overall, 303 (27%) patients had an adverse outcome, of whom 113 
(10%) died, 38 (3%) failed treatment, 75 (7%) defaulted or were lost 
to follow-up and 77 (7%) transferred out to another facility, with no 
reported treatment outcome. Patients with previously treated TB 
and those diagnosed HIV-positive before the onset of TB had higher 
risks of adverse outcomes. Overall, those who were not on CPT or 
ART had a higher risk of adverse outcome compared with those on 
CPT and ART. Among those diagnosed HIV-positive before the onset 
of TB and initiated on CPT/ART, the risk of adverse outcomes was 
higher in those starting CPT/ART before the diagnosis of TB.
DISCUSSION
There were a number of important programmatic findings from 
this nationwide study in Viet Nam. Despite a gradual increase in 
HIV testing and CPT/ART uptake in co-infected patients from 
2011 to 2013, the proportion of patients receiving TB-HIV inter-
ventions was still below the 100% recommended by the WHO.2 
Overall, less than 75% of TB-HIV patients were successfully 
treated; the main adverse outcomes were death and transfer out, 
with the latter outcome increasing between 2011 and 2013. There 
were some marked regional variations within the country: TB-HIV 
collaborative activities and associated treatment outcomes were 
worse in the mountainous regions, which are largely inhabited by 
poor people and minority groups for whom health services may 
be poor.11 These findings are not unique to Viet Nam; other coun-
tries such as Nepal experience similar difficulties with health care 
provision amongst those living in the hills and mountains.12
This retrospective cohort study in TB-HIV patients in HCMC 
showed that the main factors associated with adverse treatment 
outcomes were recurrent TB and, not surprisingly, the absence of 
CPT and ART. We have no information in our study on the profile 
of drug resistance, but those with recurrent TB may have had a 
higher risk of drug resistance, which in PLHIV compromises treat-
ment outcomes.13,14 Adjunctive CPT reduces morbidity and mor-
tality in co-infected patients before, during and after anti-tubercu-
losis treatment, and this effect is maintained even in the presence 
FIGURE 2 Uptake of ART and CPT and adverse treatment outcome in TB-HIV pa-
tients by region in Viet Nam over a 3-year period between 2011 and 2013 (n = 
13 737). ART = antiretroviral therapy; CPT = cotrimoxazole preventive therapy; TB = 
tuberculosis; HIV = human immunodeficiency virus.
TABLE 3 TB treatment outcomes among patients with TB-HIV, Viet Nam, 2011–2013*
Year
All patients with 
TB-HIV
n
Treatment success
n (%)
Died
n (%)
Failure
n (%)
Lost to follow-up
n (%)
Transferred out
n (%)
For patients with all types of TB
 2011 4675 3549 (76) 639 (14) 60 (1) 201 (4) 226 (5)
 2012 4672 3405 (73) 576 (12) 73 (2) 192 (4) 426 (9)
 2013 4390 3183 (73) 542 (12) 81 (2) 208 (5) 376 (9)
For patients with new smear-positive pulmonary TB
 2011 1932 1435 (74) 297 (16) 22 (1) 78 (4) 100 (5)
 2012 1902 1318 (69) 274 (15) 37 (2) 75 (4) 198 (10)
 2013 1773 1271 (72) 231 (13) 41 (2) 76 (4) 154 (9)
* Included TB-HIV cases who had their treatment outcomes evaluated.
TB = tuberculosis; HIV = human immunodeficiency virus; TB-HIV = HIV-associated TB.
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of ART.15 Providing ART significantly transforms the prognosis of 
co-infected TB patients in whom there is a substantial reduction 
in mortality risk.16 We do not know the precise reasons why 
PLHIV were not on ART in our study, but those diagnosed 
HIV-positive before the onset of TB may not have fulfilled the eli-
gibility criteria for starting on ART, while those diagnosed 
HIV-positive after the onset of TB may have progressed rapidly to 
death before ART was started.
Patients who were diagnosed HIV-positive before the diagnosis 
of TB had an increased risk of adverse outcomes compared with 
those diagnosed HIV-positive after TB; in the former group, starting 
CPT and ART before anti-tuberculosis treatment was associated 
with an increased risk of adverse outcomes. These findings have 
been previously reported elsewhere.17–20 One of the reasons for 
poor outcomes in those starting ART and CPT may be lower CD4 
cell counts in this group; however, we have no programmatic data 
to confirm or refute this hypothesis. Other reasons for poor out-
comes may include the unmasking of previously subclinical TB, 
difficulties and delays encountered in diagnosing TB in severely im-
munocompromised patients and paradoxical worsening of disease 
associated with immune reconstitution inflammatory syndrome.
The strengths of this study were its conduct under routine pro-
gramme conditions, the nationwide coverage with the aggregate 
data and the large number of patients registered in HCMC, mak-
ing the findings representative for the country. The study also ad-
hered to the Strengthening the Reporting of Observational Stud-
ies in Epidemiology (STROBE) guidelines for conducting and 
reporting on observational studies.21
TABLE 4 Characteristics associated with adverse TB treatment outcomes among patients with TB-HIV 
registered in Ho Chi Minh City, South-East region, Viet Nam, 2013
Variable
Evaluated for  
treatment
n
Adverse treatment 
outcome*
n (%) RR (95%CI)
All TB-HIV 1110 303 (27)
Age, years 
 0–14 1 0 –
 15–44 1012 278 (28) Reference
 45–64 93 24 (26) 0.9 (0.7–1.3)
 65 4 1 (25) 0.9 (0.2–5.0)
Sex
 Female 210 56 (27) Reference
 Male 900 247 (27) 1.0 (0.8–1.3)
Type of TB 
 Smear-negative PTB 218 63 (29) Reference
 Smear-positive PTB 569 172 (30) 1.1 (0.8–1.3)
 Extra-pulmonary TB 323 68 (21) 0.7 (0.5–1.0)
TB category
 New 752 188 (25) Reference
 Transfer in 81 27 (33) 1.3 (0.9–1.9)
 Previously treated 277 88 (32) 1.3 (1.0–1.6)†
HIV counselling and testing
 HIV diagnosed after TB 273 59 (22) Reference
 HIV diagnosed before TB 837 244 (29) 1.4 (1.1–1.7)†
TB-HIV: HIV diagnosed before TB 837 244 (29)
 CPT‡ 793 222
  CPT started during TB treatment 236 50 (21.2) Reference
  CPT started before TB treatment 505 147 (29.1) 1.4 (1.04–1.8)†
  No CPT 52 25 (48.1) 2.3 (1.6–3.3)†
 ART‡ 763 203
  ART started during TB treatment 266 57 (21.4) Reference
  ART started before TB treatment 469 127 (27.1) 1.3 (0.96–1.7)
  No ART 28 19 (67.9) 3.2 (2.3–4.5)†
TB-HIV: HIV diagnosed after TB 273 59 (22)
 CPT‡ 229 37
  Yes 205 24 (11.7) Reference
  No 24 13 (54.2) 4.6 (2.7–7.8)†
 ART‡ 223 32
  Yes 196 16 (8.2) Reference
  No 27 16 (59.3) 7.3 (4.1–12.8)†
* Adverse outcome = death, failure, loss to follow-up or transfer out.
† Statistically significant.
‡ Data missing on treatment outcomes.
TB = tuberculosis; HIV = human immunodeficiency virus; PTB = pulmonary tuberculosis; CPT = cotrimoxazole preventive ther-
apy; ART = antiretroviral therapy.
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There were some limitations. First, there were missing data in 
the VITIMES case base data file and some important variables, 
such as baseline CD4 counts, continuation of CPT and ART after 
initiation and time to events, were not yet recorded in this elec-
tronic database. The missing data in the case base data file meant 
that we had different numbers of registered patients and differ-
ent proportions with treatment outcomes in HCMC from aggre-
gate data (65% treatment success) and from individual data (73% 
treatment success). We also had nearly 13% in the VITIMES data 
file with no treatment outcomes recorded—the cells were 
blank—and we removed these from the denominator as we had 
no information about whether these patients had completed 
treatment or had an adverse outcome. As experience with the 
electronic database grows, these challenges will hopefully re-
solve. Second, we had no information in the VITIMES database 
on HIV-negative TB patients, and this may have skewed overall 
treatment outcomes. Third, our sample population with adverse 
outcomes (303 patients) was relatively small, and we therefore 
did not have sufficient power to distinguish between specific ad-
verse outcomes and risk factors. Finally, the time trend of the 
study was restricted due to VITIMES starting only in 2011 (and 
in HCMC only for 1 year).
This study has some important programmatic implications. 
First, the NTP needs to make improvements in the VITIMES data-
base to ensure that aggregate and individual data match, that all 
variables are always entered and that other variables that may 
provide useful programmatic information, as discussed earlier, are 
included.
Second, the NTP needs to increase its rates of HIV testing and 
uptake of CPT and ART in the Northern regions and the High-
lands so that the country can move rapidly to 100% coverage. 
Sustainable Development Goal 3.3 aims to end the epidemics of 
AIDS and TB by 2030,22 and concerted efforts will be needed na-
tionally with TB-HIV collaborative activities if these objectives are 
to be realised at the country level. Linked to this, the NTP also 
needs to reduce its transfer-out rates and ensure that treatment 
outcome data are available and shared between transferring out 
and transferring in centres. This can be achieved by encouraging 
greater cooperation between different TB officers.23,24
Third, mortality rates must be reduced. PLHIV should be 
started earlier on ART. The 2013 WHO ART guidelines moved the 
CD4 cell count threshold for starting ART up to 500 cells/µl,25 
and rapid advice issued by the WHO in September 2015 recom-
mended that all persons with HIV start ART, regardless of CD4 
cell count and WHO clinical stage.26 There is strong evidence that 
this approach reduces mortality,27,28 and these guidelines should 
pave the way for future countrywide implementation. Closer at-
tention is also needed to provide rapid and more accurate diagno-
sis of TB in patients with HIV, especially those who are sick and 
immunocompromised. The use of Xpert® MTB/RIF (Cepheid, 
Sunnyvale, CA, USA) at point of care in both sputum and urine, 
combined with measurement of urine lipoarabinomannan (LAM), 
holds promise, and this combined diagnostic approach needs to 
be considered within a programmatic context.29,30
In conclusion, this study shows that HIV testing rates and TB-
HIV collaborative activities are gradually improving in Viet Nam, 
although these all fall well below 100%, especially in the North-
ern and Highland regions. Treatment success is 74%, with adverse 
outcomes particularly increased in those not taking CPT and ART 
and in those developing TB after these interventions have been 
started. The Viet Nam NTP needs to address these issues if the 
country wishes to end the TB epidemic by 2030.
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Contexte  :  Le programme national tuberculose (TB) au Viet Nam et à 
Ho Chi Minh ville (HCMC).
Objectifs  :  Déterminer 1) au niveau national entre 2011 et 2013, la 
relation entre le test pour le virus de l’immunodéficience humaine 
(VIH), l’utilisation des interventions TB-VIH et les mauvais résultats du 
traitement de la TB parmi les patients TB-VIH, et 2) à HCMC en 2013, 
les caractéristiques des patients associées à un mauvais résultat.
Schéma  :  Une étude écologique revoyant les données nationales 
agrégées et une étude de cohorte rétrospective dans HCMC.
Résultats  :  Au niveau national, le test VIH est passé de 58% à 68% 
chez les patients tuberculeux et le traitement antirétroviral (ART) est 
passé chez les patients TB-VIH de 54% à 63% entre 2011 et 2013. 
Les mauvais résultats du traitement chez les patients TB-VIH ont 
augmenté de 24% à 27%, largement à cause des transferts (de 5% à 
9%) et des décès. Les régions du Nord et des Highlands ont montré 
une faible utilisation des interventions TB-VIH. A HCMC, 303 (27%) 
patients TB-VIH sur 1110 ont eu un mauvais résultat avec un risque 
plus élevé observé parmi ceux qui avaient déjà eu un traitement de 
TB, ceux dont le diagnostic de VIH précédait l’apparition de la TB et 
ceux qui n’avaient jamais bénéficié du traitement par cotrimoxazole 
et de l’ART.
Conclusion  :  En dépit de meilleurs taux de tests VIH et d’interventions 
TB-VIH, près de 26% des patients TB-VIH ont de mauvais résultats du 
traitement de la TB. Les facteurs de prédiction d’un risque plus élevé 
de mauvais résultats doivent être pris en compte si le Viet Nam 
souhaite mettre fin à l’épidémie de TB d’ici 2030.
Marco de referencia: El Programa Nacional contra la Tuberculosis 
(TB) en Viet Nam y la ciudad de Ho Chi Minh.
Objetivos: 1) Definir a escala nacional la relación entre la aceptación 
de la prueba diagnóstica de la infección por el virus de la 
inmunodeficiencia humana (VIH), las intervenciones conjuntas contra 
la TB y el VIH y los desenlaces desfavorables del tratamiento 
antituberculoso en pacientes aquejados de esta coinfección, del 2011 
y el 2013; y 2) determinar las características de los pacientes que se 
asocian con los desenlaces terapéuticos adversos en la ciudad de Ho 
Chi Minh.
Método: Se llevó a cabo un estudio ecológico, en el cual se 
examinaron los datos nacionales agregados y un estudio retrospectivo 
de cohortes en la ciudad de Ho Chi Minh.
Resultados: A escala nacional, del 2011 al 2013 se observó un 
aumento de 58% a 68% en la práctica de la prueba del VIH a los 
pacientes con diagnóstico de TB y de 54% a 63% en la administración 
del tratamiento antirretrovírico (ART) a los pacientes coinfectados. 
Los desenlaces terapéuticos desfavorables en los pacientes 
coinfectados aumentaron de 24% a 27%, debido sobre todo a las 
transferencias a otros centros (de 5% a 9%) y a los fallecimientos. En 
los regions del norte y Highland se observó una baja aceptación de 
las intervenciones conjuntas contra la TB y el VIH. En la ciudad de Ho 
Chi Minh, 303 de los 1110 pacientes coinfectados (27%) presentaron 
desenlaces adversos y el riesgo fue mayor en los pacientes con 
antecedente de tratamiento antituberculoso, en pacientes cuyo 
diagnóstico de infección por el VIH precedió el comienzo de la TB y 
en los pacientes que nunca se inscribieron al tratamiento con 
cotrimoxazol o ART.
Conclusión: Pese a los progresos en la práctica de la prueba 
diagnóstica de la infección por el VIH y las intervenciones conjuntas 
contra la TB y el VIH, la tasa de desenlaces terapéuticos desfavorables 
alcanza un 26% en los pacientes coinfectados. Es preciso abordar los 
factores que favorecen el mayor riesgo de desenlaces adversos, si se 
desea poner fin a la epidemia de TB en el 2030 en Viet Nam.
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